An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Launched by HOFFMANN-LA ROCHE · Aug 27, 2013
Trial Information
Current as of May 04, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of Avastin (bevacizumab) for women with advanced or metastatic ovarian cancer, as well as those with fallopian tube cancer or primary peritoneal cancer. The goal is to understand how safe and effective Avastin is when used in regular medical practice for these conditions. The study will continue to collect information from participants until they either finish the study, decide to leave, or unfortunately pass away.
To be eligible for this trial, participants must be women aged 65 to 74 who are either starting treatment with Avastin or are already receiving it for their advanced cancer. Those who cannot receive Avastin based on local medical guidelines will not be included. Participants can expect to share their experiences and health data throughout the study, helping researchers learn more about how Avastin works for patients like them. This information may help improve treatment options in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Prescribed to receive bevacizumab or already ongoing on treatment with bevacizumab for advanced/metastatic ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice
- Exclusion Criteria:
- • Not eligible for treatment with bevacizumab according to the local prescribing information
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangalore, Karnataka, India
Pune, Maharashtra, India
Chennai, , India
Pune, , India
Kolkata, West Bengal, India
Nashik, Maharashtra, India
Delhi, , India
New Delhi, Delhi, India
Hyderabad, , India
Ahmedabad, Gujarat, India
Nashik, Maharashtra, India
Chennai, Tamil Nadu, India
Kolkata, , India
Vijayawada, Andhra Pradesh, India
New Delhi Delhi, Delhi, India
Bangalore, Karnataka, India
Hubli, Karnataka, India
Trivandrum, Kerala, India
Aurangabad, Maharashtra, India
Mumbai, Maharashtra, India
Nagpur, Maharashtra, India
Nashik, Maharashtra, India
Pune City, Maharashtra, India
Pune, Maharashtra, India
Kolkata, West Bengal, India
Ahmedabad, , India
Bangalore, , India
Chennai, , India
Chennai, , India
Gujarat, , India
New Delhi, , India
Surat, , India
Pune, Maharashtra, India
Nashik, Maharashtra, India
Pune, Maharashtra, India
Nasik, , India
New Delhi Delhi, Delhi, India
Ahemedabad, Gujarat, India
Surat, Gujarat, India
Banglore, Karnataka, India
Chennai, Tamil Nadu, India
Chennai, Tamil Nadu, India
Hyderabad, Telangana, India
Delhi, , India
Mumbai, Maharashtra, India
Mumbai, Maharashtra, India
New Delhi, Delhi, India
Banglore, Karnataka, India
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials